Bayer's Adempas gains EU clearance for two forms of PAH

Following a previous positive opinion from the European Medicines Agency’s advisory committee (The Pharma Letter January 24), the European Commission has approved German pharma major Bayer’s (BAYN: DE) Adempas (riociguat) for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).

Adempas is indicated for the treatment of adult patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and for the treatment of adult patients with pulmonary arterial hypertension as a monotherapy or in combination with endothelin receptor antagonists. Adempas is a soluble guanylate cyclase (sGC) stimulator, and the first member of a novel class of compounds. Adempas is the first and only drug treatment approved for patients with CTEPH.

Market forecasts